Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
10 hedge funds and large institutions have $208K invested in Altamira Therapeutics Ltd in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 2 closing their positions.
174% more capital invested
Capital invested by funds: $76K → $208K (+$132K)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
25% more funds holding
Funds holding: 8 → 10 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$67.5K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$28.9K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$25.7K |
| 4 |
Morgan Stanley
New York
|
+$19.3K |
| 5 |
VF
Virtu Financial
New York
|
+$19.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$11K |
| 2 |
Barclays
London,
United Kingdom
|
-$3.21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WS
1
Wedbush Securities
Los Angeles,
California
| $59K | +$67.5K | +21 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $31K | +$28.9K | +9 | +450% |
|
|
TSS
3
Two Sigma Securities
New York
| $26K | +$25.7K | +8 | +400% |
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $25K | +$6.43K | +2 | +29% |
|
|
VF
5
Virtu Financial
New York
| $21K | +$19.3K | +6 | +300% |
|
|
6
Morgan Stanley
New York
| $17K | +$19.3K | +6 | New |
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $10K | +$12.9K | +4 | New |
|
|
CGA
8
Crescent Grove Advisors
Lake Forest,
Illinois
| $7K | – | – | – |
|
9
UBS Group
Zurich,
Switzerland
| $6K | +$3.21K | +1 | +100% |
|
|
SPC
10
Sigma Planning Corp
Ann Arbor,
Michigan
| $6K | +$6.43K | +2 | New |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$11K | -3 | Closed |
|
|
12
Barclays
London,
United Kingdom
| – | -$3.21K | -1 | Closed |
|
CYTO Hedge Fund Activity: Q1 2019 in Review
10 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q1 2019, worth a combined $208K — up 174% from $76K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CYTO positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 0 trimmed.
The largest buyer was Wedbush Securities, opening a new position worth an estimated $67.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $11K sold.
- 10 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q1 2019, up from 8 in Q4 2018.
- Funds reported $208K of Altamira Therapeutics Ltd stock for Q1 2019, up 174% quarter-over-quarter.
- 4 funds opened new Altamira Therapeutics Ltd positions in Q1 2019 and 2 closed out, a net change of +2 holders.
- The largest Altamira Therapeutics Ltd buyer in Q1 2019 was Wedbush Securities, an estimated $67.5K added.
- The largest Altamira Therapeutics Ltd seller in Q1 2019 was Citadel Advisors, an estimated $11K sold.
Based on aggregated 13F filings for Q1 2019.